UY33818A - Nueva composicion farmaceutica - Google Patents

Nueva composicion farmaceutica

Info

Publication number
UY33818A
UY33818A UY0001033818A UY33818A UY33818A UY 33818 A UY33818 A UY 33818A UY 0001033818 A UY0001033818 A UY 0001033818A UY 33818 A UY33818 A UY 33818A UY 33818 A UY33818 A UY 33818A
Authority
UY
Uruguay
Prior art keywords
new pharmaceutical
pharmaceutical composition
dimethyl
trioxo
pyrido
Prior art date
Application number
UY0001033818A
Other languages
English (en)
Inventor
Douglas J Demarini
Henriquez Francisco
Wang Lihong
Ngocdiep T Le
Original Assignee
Glaxosmithkline Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46314827&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY33818(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc
Publication of UY33818A publication Critical patent/UY33818A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/06—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of pills, lozenges or dragees
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/10—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of compressed tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2813—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se describen nuevas composiciones farmacéuticas que contienen solvato de dimetilsulfóxido de la N-{3-[3-ciclopropil-5-(2-fluoro-4-yodo-fenilamino)-6,8-dimetil-2,4,7-trioxo-3,4,6,7-tetrahidro-2H-pirido[4,3-d]pirimidin-1-il]fenil}acetamida, métodos para usar las composiciones en terapia y procedimientos para preparar las mismas.
UY0001033818A 2010-12-20 2011-12-19 Nueva composicion farmaceutica UY33818A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201061424967P 2010-12-20 2010-12-20

Publications (1)

Publication Number Publication Date
UY33818A true UY33818A (es) 2012-07-31

Family

ID=46314827

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001033818A UY33818A (es) 2010-12-20 2011-12-19 Nueva composicion farmaceutica

Country Status (36)

Country Link
US (5) US8580304B2 (es)
EP (4) EP3808343A1 (es)
JP (2) JP6126014B2 (es)
KR (1) KR101911109B1 (es)
CN (1) CN103998041B (es)
AR (2) AR084102A1 (es)
AU (1) AU2011349422B2 (es)
BR (1) BR112013015602B1 (es)
CA (1) CA2822701C (es)
CL (1) CL2013001779A1 (es)
CR (1) CR20130352A (es)
CY (1) CY1123376T1 (es)
DK (3) DK2654736T3 (es)
DO (1) DOP2013000138A (es)
EA (1) EA025198B1 (es)
ES (1) ES2820536T3 (es)
FI (2) FI4159205T3 (es)
HR (1) HRP20201409T1 (es)
HU (1) HUE050788T2 (es)
IL (1) IL226855A (es)
JO (1) JO3594B1 (es)
LT (3) LT4159205T (es)
MA (1) MA34883B1 (es)
MX (1) MX2013007073A (es)
MY (1) MY170501A (es)
NZ (1) NZ612157A (es)
PE (1) PE20140040A1 (es)
PL (1) PL2654736T3 (es)
PT (1) PT2654736T (es)
SG (1) SG191054A1 (es)
SI (1) SI2654736T1 (es)
TW (1) TWI505828B (es)
UA (1) UA113158C2 (es)
UY (1) UY33818A (es)
WO (1) WO2012088033A2 (es)
ZA (1) ZA201304189B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201708494QA (en) 2012-08-17 2017-11-29 Hoffmann La Roche Combination therapies for melanoma comprising administering cobimetinib and vemurafinib
PE20151024A1 (es) * 2012-11-30 2015-07-27 Glaxosmithkline Llc Composicion farmaceutica novedosa
WO2015019125A1 (en) * 2013-08-05 2015-02-12 Societe De Developpement Et De Recherche Industrielle Molecular targets for the treatment of wounds, in particular chronic wounds
CN103819471A (zh) * 2013-11-25 2014-05-28 镇江圣安医药有限公司 吡啶并(4,3-d)嘧啶-1（2H）-基苯基乙酰胺的衍生物及其应用
CN104918937B (zh) * 2013-12-06 2016-09-14 杭州普晒医药科技有限公司 曲美替尼及其溶剂化物的晶型、其制备方法、含有它们的药物组合物及其用途
EP2913048A1 (en) * 2014-02-27 2015-09-02 ratiopharm GmbH Pharmaceutical composition comprising trametinib
WO2016126012A1 (en) * 2015-02-05 2016-08-11 Boryung Pharmaceutical Co., Ltd Tablet and method of preparing the same
KR101545268B1 (ko) 2015-02-05 2015-08-20 보령제약 주식회사 정제 및 이의 제조방법
US20170020880A1 (en) * 2015-07-22 2017-01-26 Hetero Research Foundation Pharmaceutical compositions of trametinib
KR20230124110A (ko) 2016-08-10 2023-08-24 에프. 호프만-라 로슈 아게 Akt 단백질 키나아제 저해제를 포함하는 약학 조성물
RU2627692C1 (ru) * 2016-10-10 2017-08-10 Закрытое акционерное общество "Р-Фарм" (ЗАО "Р-Фарм") N-{ 3-[3-циклопропил-5-(2-фторо-4-иодофениламино)-6,8-диметил-2,4,7-триоксо-3,4,6,7-тетрагидро-2Н-пиридо[4,3-d]пиримидин-1-ил]-фенил} -циклопропанкарбоксамида диметилсульфоксида сольват в качестве ингибитора МЕК1/2
EP3545957A4 (en) * 2016-11-25 2020-07-22 Jiangsu Hengrui Medicine Co., Ltd. PHARMACEUTICAL PYRIDONE DERIVATIVE COMPOSITION AND PRODUCTION METHOD THEREFOR
CA3057969A1 (en) 2017-05-02 2018-11-08 Novartis Ag Combination therapy
RU2749719C1 (ru) * 2020-10-08 2021-06-16 Нестерук Владимир Викторович Препарат для лечения анемии, связанной с хроническим заболеванием почек, и способ его получения
WO2023105286A1 (en) 2021-12-06 2023-06-15 My Personal Therapeutics Ltd A combination treatment for cancer

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4727077A (en) 1985-02-20 1988-02-23 Ishihara Sangyo Kaisha Ltd. Benzoyl urea compounds, process for their production, and antitumorous compositions containing them
JPS61205257A (ja) * 1985-03-08 1986-09-11 Ishihara Sangyo Kaisha Ltd ベンゾイルウレア系化合物、その製法及びそれを含有する抗ガン剤
US5559235A (en) 1991-10-29 1996-09-24 Glaxo Wellcome Inc. Water soluble camptothecin derivatives
US5342947A (en) 1992-10-09 1994-08-30 Glaxo Inc. Preparation of water soluble camptothecin derivatives
US5681835A (en) 1994-04-25 1997-10-28 Glaxo Wellcome Inc. Non-steroidal ligands for the estrogen receptor
US5491237A (en) 1994-05-03 1996-02-13 Glaxo Wellcome Inc. Intermediates in pharmaceutical camptothecin preparation
GB9716557D0 (en) 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
US6825180B2 (en) 2001-05-18 2004-11-30 Cell Therapeutics, Inc. Pyridopyrimidine compounds and their uses
US7378423B2 (en) * 2004-06-11 2008-05-27 Japan Tobacco Inc. Pyrimidine compound and medical use thereof
MXPA06014478A (es) 2004-06-11 2007-03-21 Japan Tobacco Inc Derivados de 5-amino-2, 4, 7-trioxo-3, 4, 7, 8-tetrahidro -2h-pirido[2, 3-d]pirimidina y compuestos relacionados para el tratamiento del cancer.
WO2008048469A2 (en) * 2006-10-13 2008-04-24 Actavis Group Pct Hf Controlled-release coated dosage forms containing galantamine
US20080145433A1 (en) * 2006-11-09 2008-06-19 Gilead Colorado, Inc. Darusentan oral dosage form
JO2985B1 (ar) * 2006-12-20 2016-09-05 Takeda Pharmaceuticals Co مثبطات كينازmapk/erk
UY30892A1 (es) 2007-02-07 2008-09-02 Smithkline Beckman Corp Inhibidores de la actividad akt
ECSP077628A (es) * 2007-05-03 2008-12-30 Smithkline Beechman Corp Nueva composición farmacéutica
EP2175885B1 (en) * 2007-07-30 2016-10-12 Ardea Biosciences, Inc. Combinations of mek inhibitors and raf kinase inhibitors and uses thereof
US20090087489A1 (en) * 2007-09-25 2009-04-02 Bella Gerber Imatinib compositions
CN104592242B (zh) 2008-07-08 2017-01-25 贝达药业股份有限公司 埃克替尼盐酸盐晶型、药物组合物和用途
MX2012003546A (es) 2009-09-23 2012-09-07 Glaxosmithkline Llc Combinacion.
CA2775125C (en) 2009-09-23 2019-01-08 Glaxosmithkline Llc Combination of a mek inhibitor and an akt inhibitor to treat cancer
CN102665719A (zh) 2009-09-28 2012-09-12 葛兰素史密斯克莱有限责任公司 组合
PL2488033T3 (pl) * 2009-10-16 2019-12-31 Novartis Ag Kombinacja zawierająca inhibitor MEK i inhibitor B-raf
AU2010322105B2 (en) 2009-11-17 2014-05-08 Novartis Ag Combination
EP2608790A4 (en) 2010-08-26 2014-04-02 Glaxosmithkline Llc PHARMACEUTICAL COMBINATION OF A VEGFR-INHIBITOR AND A MEK-INHIBITOR FOR THE TREATMENT OF CANCER
US8977217B1 (en) 2013-02-20 2015-03-10 Triquint Semiconductor, Inc. Switching device with negative bias circuit

Also Published As

Publication number Publication date
US9155706B2 (en) 2015-10-13
EP2654736A4 (en) 2015-04-22
BR112013015602B1 (pt) 2022-03-03
SI2654736T1 (sl) 2020-10-30
MY170501A (en) 2019-08-08
TW201249441A (en) 2012-12-16
AU2011349422A1 (en) 2013-05-02
LT4159205T (lt) 2024-05-10
US20130266649A1 (en) 2013-10-10
CA2822701C (en) 2018-10-23
US20140099365A1 (en) 2014-04-10
US8580304B2 (en) 2013-11-12
US20140037726A1 (en) 2014-02-06
HRP20201409T1 (hr) 2020-11-27
SG191054A1 (en) 2013-08-30
JP2014510704A (ja) 2014-05-01
EP3808343A1 (en) 2021-04-21
US20120183613A1 (en) 2012-07-19
EP4159204A1 (en) 2023-04-05
EP4159205B1 (en) 2024-02-14
IL226855A (en) 2017-04-30
CL2013001779A1 (es) 2014-06-27
HUE050788T2 (hu) 2021-01-28
NZ612157A (en) 2015-05-29
CN103998041B (zh) 2016-08-17
MX2013007073A (es) 2013-09-26
LT2654736T (lt) 2020-09-25
JO3594B1 (ar) 2020-07-05
AR084102A1 (es) 2013-04-24
JP6126014B2 (ja) 2017-05-10
EA201390913A1 (ru) 2014-04-30
TWI505828B (zh) 2015-11-01
BR112013015602A2 (pt) 2017-02-21
CR20130352A (es) 2013-12-18
AU2011349422B2 (en) 2015-12-10
PT2654736T (pt) 2020-09-24
KR20130130028A (ko) 2013-11-29
WO2012088033A2 (en) 2012-06-28
PL2654736T3 (pl) 2020-12-14
DOP2013000138A (es) 2013-11-30
CA2822701A1 (en) 2012-06-28
LT4159204T (lt) 2024-05-10
DK2654736T3 (da) 2020-09-14
US9271941B2 (en) 2016-03-01
ZA201304189B (en) 2014-02-26
FI4159204T3 (fi) 2024-04-22
JP2017137299A (ja) 2017-08-10
CN103998041A (zh) 2014-08-20
KR101911109B1 (ko) 2018-10-23
EA025198B1 (ru) 2016-11-30
US20140154316A1 (en) 2014-06-05
ES2820536T3 (es) 2021-04-21
PE20140040A1 (es) 2014-02-26
DK4159205T3 (da) 2024-05-13
UA113158C2 (xx) 2016-12-26
EP4159204B1 (en) 2024-02-14
EP2654736A2 (en) 2013-10-30
WO2012088033A3 (en) 2014-03-13
CY1123376T1 (el) 2021-12-31
DK4159204T3 (da) 2024-05-21
EP2654736B1 (en) 2020-07-01
US9399021B2 (en) 2016-07-26
FI4159205T3 (fi) 2024-04-23
EP4159205A1 (en) 2023-04-05
MA34883B1 (fr) 2014-02-01
AR122185A2 (es) 2022-08-24

Similar Documents

Publication Publication Date Title
DOP2013000138A (es) Nueva composición farmacéutica
CL2020000031A1 (es) Aparatos y métodos de cribas moldeadas por inyección. (divisional solicitud 201801786).
UY35157A (es) Nueva composición farmacéutica conteniendo dimetilsulfóxido
UY34578A (es) Nuevos derivados de indolizina, su procedimiento de preparación y las composiciones farmacéuticas q ue los contienen
BR112014001050A2 (pt) copolímero em bloco de poliéster poliamida, método para a preparação do mesmo, composição, produtos de liberação controlada e de cuidado pessoal, e, método para preparação de uma composição de gel
NI201200072A (es) Métodos y composiciones para tratar cáncer
CL2014003232A1 (es) Formulaciones y métodos para la administración vaginal de antiprogestinas.
CL2013000018A1 (es) Compuestos derivados de indolizina , su procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento del cancer, entre otros.
SV2010003559A (es) Algunos derivados de 2-pirazinona y su uso como inhibidores de elastasa de los neutrofilos
AR125920A2 (es) Composiciones que comprenden vortioxetina y donepezil
DOP2009000215A (es) Administracion semanal de inhibidores de peptidasa de pipeptidilo
CR9786A (es) Compuestos de bencimidazol-tiofeno
UY30308A1 (es) Moduladores de mglur5 v
BR112013013930A2 (pt) método para criar um produto de sementes misturadas de alta precisão, método para fazer a separação entre dois ou mais grupos de sementes e um produto de mistura de sementes
UY30307A1 (es) Moduladores de mglur5 vi
UY30306A1 (es) Moduladores de mglur5 iii
MY191875A (en) Solid dosage form
CL2008002545A1 (es) Compuestos derivados de fenoxi-bencil-carbamoilo; composicion farmaceutica; procedimiento para preparar la composicion farmaceutica; y su uso en el tratamiento del dolor.
BR112012029824A2 (pt) métodos para o preparo de cloreto de glicopirrônio, cloreto de glicopirrônio, composição farmacêutica e uso de cloreto de glicopirrônio
MX2014008390A (es) Formulaciones de romidepsina y sus usos.
CU20130124A7 (es) Derivados de tieno [2,3-d] pirimidina y su uso para el tratamiento de la arritmia
UY34031A (es) Componente de éster aromático en la formulación de composiciones agroquímicas
CO6781490A2 (es) Nueva composición farmacéutica
AU2013338098A8 (en) Solid salt form of alpha-6-mPEG6-O-hydroxycodone as opioid agonists and uses thereof
BR112014032456A2 (pt) métodos in vitro, composição farmacêutica, kit para realização do método e método para melhorar o efeito de tratamento

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20211104

110 Patent granted

Effective date: 20221019